Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
LA JOLLA, Calif. - CalciMedica Inc. (NASDAQ:CALC), a clinical-stage biopharmaceutical company with a market capitalization of $45.5 million, announced Tuesday a collaboration with clinical trial intelligence company Telperian to integrate artificial intelligence tools into the analysis of clinical trial datasets for its lead compound Auxora. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 5.45, though it faces significant cash burn challenges.
The partnership will focus on analyzing data from completed trials, including the Phase 2b CARPO trial in acute pancreatitis patients and Phase 2 CARDEA trial in COVID-19 pneumonia patients. Telperian’s AI platform will help identify patient subtypes that may benefit most from treatment and refine endpoints for upcoming pivotal trials. With analyst price targets ranging from $14 to $20, Wall Street appears optimistic about the company’s clinical development strategy.
Auxora, a calcium release-activated calcium (CRAC) channel inhibitor, is being developed for acute inflammatory and immunologic illnesses. CalciMedica is currently in discussions with the FDA on a final pivotal trial design for Auxora in acute pancreatitis.
"Telperian’s advanced AI engine will be beneficial in the further analysis of these trials, allowing us to dig deeper into the effects of Auxora," said Rachel Leheny, CEO of CalciMedica, in the press release statement.
The company is also conducting a Phase 2 KOURAGE trial evaluating Auxora in patients with acute kidney injury with respiratory failure, with data expected in early 2026.
Telperian’s platform combines AI, biostatistics, and domain expertise to provide insights into treatment benefits across different patient populations. The company will also conduct emulations of historical studies in critical care to support CalciMedica’s regulatory discussions.
CalciMedica’s Auxora has been administered to over 350 critically ill patients across multiple clinical trials, according to the company. The stock has shown strong momentum with a 100% price return over the past six months, despite current market challenges. Discover more insights and 8 additional key metrics with InvestingPro’s comprehensive analysis tools.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.